Charles River Laboratories International, Inc. (CRL) Shares Outstanding: 0.05
Is Charles River Laboratories International, Inc.’s shares outstanding high or low?
Charles River Laboratories International, Inc.'s shares outstanding of 0.05 is in line with its 5-year average of 0.05, near the low end of its 5-year range (0.05–0.05).
1.80% below its 12-month average of 0.05.
CRL Shares Outstanding Chart
CRL Average Shares Outstanding Chart
CRL Current vs Average Shares Outstanding Chart
CRL Shares Outstanding Metrics
SHARES OUTSTANDING
0.05
SHARES OUTSTANDING AVG TTM
0.05
SHARES OUTSTANDING AVG 3Y
0.05
SHARES OUTSTANDING AVG 5Y
0.05
SHARES OUTSTANDING AVG 10Y
0.05
SHARES OUTSTANDING AVG 15Y
0.05
SHARES OUTSTANDING AVG 20Y
0.05
CURRENT VS TTM AVG
-1.80%
CURRENT VS 3Y AVG
-2.33%
CURRENT VS 5Y AVG
-1.80%
CURRENT VS 10Y AVG
+0.87%
CURRENT VS 15Y AVG
-0.39%
CURRENT VS 20Y AVG
-8.23%
Share Structure
Shares Outstanding
49.56M
Float Shares
N/A
Stock Price
$186.29
Market Cap
$8.9B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 49.56M | -3.53% |
| 2024 | 51.38M | +0.30% |
| 2023 | 51.23M | +0.82% |
| 2022 | 50.81M | +1.03% |
| 2021 | 50.29M | +1.50% |
| 2020 | 49.55M | +1.68% |
| 2019 | 48.73M | +1.63% |
| 2018 | 47.95M | +0.98% |
| 2017 | 47.48M | +0.99% |
| 2016 | 47.01M | +1.11% |
| 2015 | 46.50M | -0.28% |
| 2014 | 46.63M | -2.33% |
| 2013 | 47.74M | -0.36% |
| 2012 | 47.91M | -5.73% |
| 2011 | 50.82M | -18.76% |
| 2010 | 62.56M | -4.29% |
| 2009 | 65.37M | -2.84% |
| 2008 | 67.27M | +0.47% |
| 2007 | 66.96M | -2.77% |
| 2006 | 68.87M | -1.06% |
| 2005 | 69.61M | +40.33% |
| 2004 | 49.60M | +8.92% |
| 2003 | 45.54M | +1.74% |
| 2002 | 44.76M | +8.72% |
| 2001 | 41.17M | +46.72% |
| 2000 | 28.06M | +41.57% |
| 1999 | 19.82M | +92.70% |
| 1998 | 10.29M | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Charles River Laboratories International, Inc. Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Charles River Laboratories International, Inc. Shares Outstanding FAQ
- What is the shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The shares outstanding for CRL stock is 0.05.
- Is Charles River Laboratories International, Inc.'s shares outstanding high or low?
- Charles River Laboratories International, Inc.'s shares outstanding of 0.05 is in line with its 5-year average of 0.05, near the low end of its 5-year range (0.05–0.05).
- What is the TTM average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The TTM average shares outstanding for CRL stock is 0.05.
- What is the 3Y average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The 3Y average shares outstanding for CRL stock is 0.05.
- What is the 5Y average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The 5Y average shares outstanding for CRL stock is 0.05.
- What is the 10Y average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The 10Y average shares outstanding for CRL stock is 0.05.
- What is the 15Y average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The 15Y average shares outstanding for CRL stock is 0.05.
- What is the 20Y average shares outstanding for Charles River Laboratories International, Inc. (CRL)?
- The 20Y average shares outstanding for CRL stock is 0.05.
Charles River Laboratories International, Inc. Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-27 | 0.05 |
| 2024-12-28 | 0.05 |
| 2023-12-31 | 0.05 |
| 2022-12-31 | 0.05 |
| 2021-12-31 | 0.05 |
| 2020-12-31 | 0.05 |
| 2019-12-31 | 0.05 |
| 2018-12-31 | 0.05 |
| 2017-12-31 | 0.05 |
| 2016-12-31 | 0.05 |
| 2015-12-31 | 0.05 |
| 2014-12-31 | 0.05 |
| 2013-12-31 | 0.05 |
| 2012-12-31 | 0.05 |
| 2011-12-31 | 0.05 |
| 2010-12-31 | 0.06 |
| 2009-12-31 | 0.07 |
| 2008-12-31 | 0.07 |
| 2007-12-31 | 0.07 |
| 2006-12-31 | 0.07 |
| 2005-12-31 | 0.07 |
| 2004-12-31 | 0.05 |
| 2003-12-31 | 0.05 |
| 2002-12-31 | 0.04 |
| 2001-12-31 | 0.04 |
| 2000-12-31 | 0.03 |
| 1999-12-31 | 0.02 |
| 1998-12-31 | 0.01 |
Related Metrics
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster